Objective: Cervical cancer (CC) tops the list as the most prevalent malignant tumors of the female reproductive system and is one of the leading causes of cancer-related deaths in women worldwide. To improve the prognosis of CC, research has consistently focus on understanding innovative approaches. Biomarker-guided precision medicine is an important direction to improve prognosis. In this paper, we aim to deepen our understanding of CC biomarkers and accelerate their translation into clinical practice. Mechanism: Literature studies on biomarkers for CC were screened from 23 May 2019 to 23 May 2023. A comprehensive search was performed in NIH/NCBI/PubMed databases. Findings in Brief: There are numerous biomarkers that have a significant role in the diagnosis, prognosis, and treatment of CC. They can influence various processes such as tumour proliferation, invasion, infiltration, and apoptosis. They are also related closely to the sensitivity and resistance of radiotherapy and chemotherapy. Conclusions: To date, multiple CC biomarkers have been identified. Few biomarkers have been successfully applied in clinical practice due to the lack of validation in large-scale clinical studies. Therefore, further clinical studies are necessary to realize the great potential in the clinic.